ArticleJournal of diabetes and metabolic disorders2021
Association of IL-16 rs11556218 T/G polymorphism with the risk of developing type 2 diabetes mellitus.
Article in Journal of diabetes and metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 12 citations in OpenAlex.
- Association of IL16 rs11556218 and IL1B rs16944 polymorphisms with type 2 diabetes in the Kinh Vietnamese population.PloS one · 2026Article
- Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer.International journal of molecular sciences · 2024Article
- Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor.Scientific reports · 2024Article
- Analysis of differentially expressed genes in torn rotator cuff tendon tissues in diabetic patients through RNA-sequencing.BMC musculoskeletal disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetes mellitus is a chronic disorder that has serious complications. Type 2 diabetes mellitus is more widespread worldwide and in Egypt. Interleukin-16 is a pro-inflammatory factor that can lead to many inflammatory diseases by stimulating the secretions of cytokines. Inflammation and obesity are concomitant factors that may lead to insulin resistance and type 2 diabetes mellitus. In this study, we tried to focus on the relation between Interleukin-16 rs11556218 polymorphism and the risk of development of type 2 diabetes mellitus. PATIENTS AND
methods128 type 2 diabetic patients and 128 healthy individuals as control were included in this case-control study. Interleukin-16 gene polymorphism (SNP rs11556218 T/G) was genotyped using a real-time polymerase chain reaction.
resultsInterleukin-16 rs11556218 T/G gene polymorphism has a statistically significant association with type 2 diabetes mellitus in the co-dominant, dominant and, over dominant genetic models. The genotype TG was presented in approximately 30 % of diabetic patients vs. control (p = 0.04) and patients with TG genotype have a 1.8 times higher risk for developing type 2 diabetes mellitus (OR1.87; 95 % CI = 1.04 to 3.39) and 9.5 times higher after risk-adjusted diabetes (OR9.58; 95 % CI = 1.50 to 61.25) (p = 0.031). We found an association between Interleukin-16 gene polymorphism with both body mass index and high density lipoprotein.
conclusionThis study is the first one in the Middle East and Africa which found a correlation between Interleukin-16 gene polymorphism rs11556218 and type 2 diabetes mellitus. Egyptians with TG genotypes have a higher risk to develop type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.